The Myeloma Drug Tracker shows where drugs are in the clinical trial pathway as potential treatments for myeloma. Available drugs are ones which have already been licensed for use in myeloma.
Using the filters below, you can explore the drug types and trial stages. Clicking on a drug will provide additional information and you can download an Infosheet if there is one available.
Further information can be found on our website under Clinical Trials and Novel Drugs.
Filter by drug type
12 Immunotherapy
6 Epigenetic Drug
3 Proteasome Inhibitor
7 Cell Signalling/Cycle
Filter by trial stage
Order by
Drug name
Drugs in Phase I
I
Drugs in Phase II
II
Drugs in Phase III
III
Available Drugs
A
Other | Drugs in Phase I
Uproleselan is a new drug being tested for myeloma. Uprolselan is thought to improve the overall impact of myeloma treatment by reducing the number of myeloma cells sticking to bone marrow through the inhibition of E-selectin. E-selectin is a type of a cell adhesion molecule which is involved in the binding of myeloma cells to bone marrow. google
Other | Drugs in Phase I
s55746 is a new drug being investigated as a treatment for myeloma. It belongs to a class of drugs known as BCL-2 inhibitors, which work by accelerating cancer cell death.
Epigenetic Drug | Drugs in Phase I
CXD101 is a new drug being investigated as a treatment for myeloma and other cancers. It belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors.
Other | Drugs in Phase I
CC-92480 is a new drug being invesitgated as a treatment for myeloma. It is a cereblon E3 ubiquitin ligase modulating drug (CELMoD®).
Cell Signalling/Cycle | Drugs in Phase II
KW-2478 is a new drug being investigated as a treatment for myeloma in combination with other drugs. It is a heat shock protein 90 (HSP90) inhibitor that can prevent the growth of myeloma cells.
Other | Available Drugs
Pamidronate, also known as Aredia® is used in the treatment and prevention of myeloma bone disease. It belongs to a class of drug known as bisphosphonates.
Immunotherapy | Drugs in Phase II
AUTO2 is a new treatment being investigated in myeloma. It belongs to a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy. CAR-T cells are immune cells (T-cells), taken from the patient, which are genetically engineered to recognise myeloma cells more easily. AUTO2 is the first dual targeting CAR-T cell therapy, as it is designed to target 2 proteins found on the surface of myeloma cells; B-cell maturation antigen (BCMA) and transmembrane activator, calcium modulator and cyclophilin ligand interactor (TACI). AUTO2 attaches to the proteins then removes and destroys the myeloma cells.
Cell Signalling/Cycle | Drugs in Phase I
AZD4573 is a new drug being investigated as a treatment for myeloma and other haematological malignancies. It is a cyclin dependent kinase 9 (CDK9) inhibitor.
Epigenetic Drug | Drugs in Phase I
RO6870810 is a drug being investigated as a treatment for myeloma. It belongs to a class of drugs known as BET protein bromodomain inhibitors and works by interfering with the structure of DNA, leading to cell death.
Epigenetic Drug | Drugs in Phase I
GSK525762 is a new drug being investigated as a treatment for myeloma. It belongs to a novel class of drugs called BET protein bromodomain inhibitors and works by interfering with the structure of DNA, leading to cell death.
Immunotherapy | Drugs in Phase II
CC-220 is a new drug being tested for the treatment of myeloma. CC-220 is an immunomodulatory drug which like thalidomide, lenalidomide and pomalidomide targets a protein called cereblon. Cereblon has a number of functions and therefore inhibition of celebron causes myeloma cells to stop functioning properly leading to myeloma cell death.
Immunotherapy | Drugs in Phase II
What is it?
BB2121 is a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T cell) therapy. BB2121 is currently being tested in Phase II trials in the US.
How does it work?
CAR-T cells are a new type of treatment that uses the body’s own immune system to kill myeloma cells. CAR-T cells are made by taking T-cells (a type of immune cell) from the patient and modifying them to recognise myeloma cells more easily. BB2121 is modified to recognise a protein found on the surface of myeloma cells, BCMA (B cell maturation antigen). This means that BB2121 can identify and kill myeloma cells.
Cell Signalling/Cycle | Drugs in Phase I
Buparlisib is a new oral drug being investigated as a treatment for myeloma. It belongs to a class of drug known as a phosphatidlyinositol 3-kinase (PI3 kinase) inhibitor and works by disrupting the cell signals that control the growth and survival of myeloma cells, causing them to die.
Cell Signalling/Cycle | Drugs in Phase II
DTP3 is a new drug being tested in myeloma. It belongs to a class of drugs which works by inhibiting the NF KB signalling pathway, thus preventing the growth and survival of myeloma cells.
Immunotherapy | Drugs in Phase II
GSK2857916 is a new drug being investigated as a treatment for myeloma. It consists of a chemotherapy drug attached to an antibody which targets a protein on myeloma cells. GSK2857916 targets a protein called B cell maturation antigen (BCMA). This type of drug is called an antibody-drug conjugate.
Other | Drugs in Phase I
Reolysin is a new treatment being investigated in myeloma and other cancers. It is as an oncolytic virus, a type of virus that preferentially infects and kills cancer cells.
Immunotherapy | Available Drugs
Thalidomide is a drug that is used as a treatment for myeloma. It belongs to a class of `drugs called immunomodulatory drugs (IMiDs).
Immunotherapy | Drugs in Phase III
What is it?
Pembrolizumab is an immune checkpoint inhibitors. It is has been evaluated in a number of trials for the treatment of relapsed/refractory myeloma patients.
How does it work?
The immune system should kill harmful cells. It uses a series to of checks to differentiate between healthy and harmful cells. Myeloma cells exploit this checkpoint system to stop the immune system killing them. Immune checkpoint inhibitors are drugs which reduce the ability of myeloma cells to exploit the checkpoint system.
Immunotherapy | Available Drugs
Revlimid is a drug that is used as a treatment for myeloma. It belongs to a class of drugs called immunomodulatory drugs (IMiDs) and is a derivative of thalidomide.
Other | Drugs in Phase III
Selinexor, previously known as KPT-330, is the first in a new class of drugs being investigated as a treatment for myeloma. It belongs to a class of drug called selective inhibitor of nuclear export (SINE) and works by disrupting survival mechanisms in myeloma cells.
Immunotherapy | Available Drugs
Pomalidomide is a drug used as a treatment for myeloma. It is a derivative of thalidomide and belongs to a class of drugs called immunomodulatory drugs (IMiDs).
Other | Drugs in Phase III
Venetoclax (previously ABT-199) is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as BCL-2 inhibitors, which work by accelerating cancer cell death.
Other | Available Drugs
Dexamethasone is a steroid drug which is given alone or in combination with other drugs as a treatment for myeloma.
Other | Available Drugs
Prednisolone is a steroid drug which is given alone or in combination with other drugs as a treatment for myeloma.
Other | Available Drugs
Mozobil is a drug used to help mobilise stem cells from the bone marrow into the blood so that they can be harvested in preparation for high-dose therapy and stem cell transplantation.
Immunotherapy | Drugs in Phase III
What is it?
Nivolumab is an immune checkpoint inhibitors. It is currently being evaluated in a number of trials for the treatment of relapsed/refractory myeloma patients.
How does it work?
The immune system should kill harmful cells. It uses a series to of checks to differentiate between healthy and harmful cells. Myeloma cells exploit this checkpoint system to stop the immune system killing them. Immune checkpoint inhibitors are drugs which reduce the ability of myeloma cells to exploit the checkpoint system.
Immunotherapy | Drugs in Phase III
What is it?
Isatuximab is a next generation monoclonal antibody. It is currently being evaluated in Phase 3 trials for the treatment of relapsed/refractory myeloma patients.
How does it work?
It works by attaching to a protein found on the surface of myeloma cells, CD38. It has been shown to kill myeloma cells directly and to help the immune system to better target and kill myeloma cells.
Cell Signalling/Cycle | Drugs in Phase II
Vemurafenib is a drug being investigated as a treatment for myeloma and other cancer patients who specifically have the BRAF V600E mutation. It belongs to a class of drugs known as protein kinase inhibitors and specifically targets the B-RAF enzyme.
Epigenetic Drug | Drugs in Phase II
CHR 3996 is a new drug being investigated as a treatment for myeloma. It belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors.
Other | Drugs in Phase II
Tosedostat is a new drug being investigated as a treatment for myeloma. It belongs to a class of drugs known as aminopeptidase inhibitors.
Proteasome Inhibitor | Available Drugs
What is it?
Carfilzomib is an proteasome inhibitor. Its approved in combination with dexamethasone as a 2nd line treatment for myeloma patients.
How does it work?
It works by blocking the actions of proteasomes. Proteasomes are large molecules found in all cells of the body, and they are involved in the breakdown of damaged or unwanted proteins. Carfilzomib temporarily blocks their function, stopping them from breaking down unwanted proteins. This causes proteins to build up to toxic levels, killing the cell. Myeloma cells rely more heavily on proteasomes than normal healthy cells; they are therefore much more sensitive to carfilzomib.
Proteasome Inhibitor | Available Drugs
What is it?
Bortezomib is an proteasome inhibitor. It’s approved for use for newly diagnosed and relapsed/refractory myeloma patients.
How does it work?
It works by blocking the actions of proteasomes. Proteasomes are large molecules found in all cells of the body, and they are involved in the breakdown of damaged or unwanted proteins. Bortezomib temporarily blocks their function, stopping them from breaking down unwanted proteins. This causes proteins to build up to toxic levels, killing the cell. Myeloma cells rely more heavily on proteasomes than normal healthy cells; they are therefore much more sensitive to bortezomib.
Chemotherapy | Available Drugs
Cyclophosphamide is a chemotherapy drug used as a treatment for myeloma and other cancers.
Chemotherapy | Available Drugs
Melphalan is a chemotherapy drug used as a treatment for myeloma and other cancers.
Chemotherapy | Available Drugs
Etoposide is a chemotherapy drug used as a treatment for myeloma and other cancers.
Chemotherapy | Available Drugs
Cisplatin is a chemotherapy drug used as a treatment for myeloma and other cancers.
Epigenetic Drug | Available Drugs
Panobinostat is a drug being used as a treatment for myeloma. It belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors.
Chemotherapy | Available Drugs
Doxorubicin is a chemotherapy drug used as a treatment for myeloma and other cancers.
Chemotherapy | Available Drugs
Bendamustine is a chemotherapy drug used as a treatment for myeloma and other cancers.
Immunotherapy | Drugs in Phase III
What is it?
Elotuzumab is a monoclonal antibody. It has been approved for use in the US and Europe in combination with lenalidomide and dexamethasone but it is not currently available through the NHS in the UK.
How does it work?
It works by attaching to a protein found on the surface of myeloma cells, SLAM-7. Elotuzumab attaches to SLAM-7 making the myeloma cell more visible to the immune system. This allows the immune system to target and kill the myeloma cell.
Other | Drugs in Phase III
Plitidepsin is a novel anti-cancer drug of marine origin that is being investigated for as a treatment for myeloma.
Epigenetic Drug | Drugs in Phase III
Vorinostat is a new drug being investigated as a treatment for myeloma and other cancers. It belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors.
Immunotherapy | Available Drugs
What is it?
Daratumumab is a monoclonal antibody. Daratumumab has been approved for myeloma patients in England, Scotland and Wales as a 4th line treatment. It is also approved in combination with bortezomib and dexamethasone for myeloma patients in England as a 2nd line treatment.
How does it work?
It works by attaching to a protein found on the surface of myeloma cells, CD38. Daratumumab attaches to CD38 making the myeloma cell more visible to the immune system. This allows the immune system to target and kill the myeloma cell.
Proteasome Inhibitor | Available Drugs
What is it?
Ixazomib is an oral proteasome inhibitor. Its approved in combination with lenalidomide and dexamethasone as a 2nd or 3rd line treatment for myeloma patients.
How does it work?
It works by blocking the actions of proteasomes. Proteasomes are large molecules found in all cells of the body, and they are involved in the breakdown of damaged or unwanted proteins. Ixazomib temporarily blocks their function, stopping them from breaking down unwanted proteins. This causes proteins to build up to toxic levels, killing the cell. Myeloma cells rely more heavily on proteasomes than normal healthy cells; they are therefore much more sensitive to ixazomib.
Chemotherapy | Drugs in Phase III
What is it?
Melflufen is a in active form of melphalan, in which melphalan is bound to a peptide (small protein). Melflufen is being investigated for the treatment of relapsed/refractory myeloma patients in a phase III trial in the UK.
How does it work?
Melflufen targets myeloma cells using peptidases (enzymes which breakdown peptides) which are often found at higher concentrations in myeloma cells. The peptidases in the myeloma cells break up melflufen releasing active melphalan. The melphalan can then kill the myeloma cell.
Cell Signalling/Cycle | Drugs in Phase II
Filanesib, previously known as ARRY-520, is a new drug being investigated for the treatment of myeloma. It belongs to a class of drugs known as kinesin spindle inhibitors and inhibits cell division.
